7.09k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
LLY439.523.03%
Eli Lilly and Company
JNJ154.590.05%
Johnson & Johnson
NVO155.46-2.52%
Novo Nordisk A/S
MRK110.80-0.13%
Merck & Co., Inc.
RHHBY39.970.38%
Roche Holding AG
ABBV134.210.77%
AbbVie Inc.
AZN72.940.10%
AstraZeneca PLC
PFE38.290.26%
Pfizer Inc.
NVS98.231.12%
Novartis AG
BMY64.68-
Bristol-Myers Squibb Company
SNY50.730.27%
Sanofi
AMGN213.30-0.97%
Amgen Inc.
GILD76.00-0.21%
Gilead Sciences, Inc.
VRTX323.25-0.37%
Vertex Pharmaceuticals Incorporated
REGN728.63-2.54%
Regeneron Pharmaceuticals, Inc.
ZTS167.421.41%
Zoetis Inc.
GSK33.960.16%
GSK plc
BAYRY13.98-
Bayer Aktiengesellschaft
TAK16.130.23%
Takeda Pharmaceutical Company Limited
MRNA129.831.31%
Moderna, Inc.
BIIB298.77-3.64%
Biogen Inc.
HLN8.270.12%
Haleon plc
SGEN194.720.05%
Seagen Inc.
BNTX107.733.61%
BioNTech SE
GMAB39.16-0.18%
Genmab A/S
ALNY190.531.86%
Alnylam Pharmaceuticals, Inc.
HZNP99.95-0.45%
Horizon Therapeutics Public Limited Company
ARGX396.211.55%
argenx SE
BMRN88.710.45%
BioMarin Pharmaceutical Inc.
RPRX33.380.21%
Royalty Pharma plc
Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain was sparked by the company's research and development day presentation held on Wednesday. Highlights from Biohaven's presentation include the unexpected Food and Drug Administration (FDA) regulatory filing for the experimental spinocerebellar ataxia type 3 drug troriluzole, status updates on its closely watched epilepsy program, and a clinical strategy overview for its newly acquired neuroinflammatory asset BHV-8000.
Many high-quality dividend stocks currently yield around 3%, nearly double that of the S&P 500. American Tower's dividend yield is currently over 3%, a historically high rate for the data-infrastructure real estate investment trust (REIT). The company has an exceptional track record of paying dividends.
Novartis breast cancer drug Kisqali cut the risk of recurrence by a little more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and challenging strong rival Eli Lilly. The company on Friday said the relative risk reduction of cancer recurrence was 25.2% and that the results were broadly consistent regardless of patients' menopausal status or cancer progression status. The results were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.Kisqali was used in the trial together with standard endocrine therapy to treat a type of cancer that grows in response to hormones and it was compared to endocrine therapy alone.
Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib; CDK4/6 inhibitor) and Jaypirca™ (pirtobrutinib; non-covalent (reversible) BTK inhibitor) data to be presented at the 2023 ASCO® Annual Meeting in Chicago, June 2 – 6, 2023. Presentations include new analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high risk early breast canc
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of disease stage, menopausal or nodal status1 Results were also consistent across all secondary endpoints, including distant disease-free survival and recurrence-free survival, with a trend for improved overall survival*1 The safety profile of Kisqali was favorable at 400 mg with low rates of symptomatic adv
BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc was shown to shrink tumours in close to 30% of participants in a mid-stage lung cancer trial. The experimental drug, known as gotistobart, was tested on patients with metastatic non-small cell lung cancer which could no longer be helped by a group of so-called checkpoint inhibitor drugs such as Merck & Co's Keytruda. A follow-on trial in the third and last phase of testing typically required for approval would start in the third quarter of this year, BioNTech added in its statement.
Bayer (BAYRY) announces licensing agreement with Cedilla Therapeutics to jointly develop and commercialize the latter's selective protein complex inhibitors as novel cancer therapies.
Key Insights Given the large stake in the stock by institutions, Bristol-Myers Squibb's stock price might be vulnerable...
Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have...
BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications, including non-small cell lung cancer (NSCLC)Interim data of BNT316/ONC-392 from the ongoing Phase 1/2 trial to be presented at this year’s ASCO Annual Meeting demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety profile in patients with metastatic, PD-(L)1-resistant NSCL
Takeda is doubling down on research and development in the Boston area with a host of new drugs in development for rare diseases, cancer, dengue and Covid-19.
The AI in healthcare market is expected to top $100 billion by the end of the decade, and some companies are already leveraging this technology to advance their work. Two great examples are Moderna (NASDAQ: MRNA) and Doximity (NYSE: DOCS). Moderna isn't a novice when it comes to AI.
These phenomenal businesses have the tools and intangibles to make patient shareholders a lot richer.
NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance are included in this Analyst Blog.
With its stock down 8.9% over the past month, it is easy to disregard Haleon (LON:HLN). We, however decided to study...
Bristol Myers Squibb (BMY) closed the most recent trading day at $64.68, moving +0.37% from the previous trading session.
Medicare plans to widen coverage of Alzheimer’s drugs that could win full approval as soon as this summer. The Centers for Medicare and Medicaid Services on Thursday said it would cover Biogen and Eisai treatment Leqembi if the drug wins full approval and patients and doctors contribute to a registry that collects evidence on how the medication works. Most Alzheimer’s patients in the U.S. are Medicare enrollees.
A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs' misuse of confidential records they obtained through related litigation. The lawsuit, which accused J&J's DePuy Orthopaedics unit of defrauding the federal government by marketing defective hip implants, was dismissed in December 2021. J&J has denied wrongdoing.
Is Pfizer stock a buy after the company unveiled promising weight-loss results for its diabetes pill? Is PFE stock a buy or a sell right now?
The Dow Jones Industrial Average moved higher by more than 0.5%, or 153 points, as investors celebrated the House of Representatives passage of the debt-ceiling bill, which now goes to the Senate.
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Bristol-Myers Squibb Company (BMY) and ICICI Bank Limited (IBN).
A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs' misuse of confidential records they obtained through related litigation. The lawsuit, which accused J&J's DePuy Orthopaedics unit of defrauding the federal government by marketing defective hip implants, was dismissed in December 2021. J&J has denied wrongdoing.
A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs' misuse of confidential records they obtained through related litigation. The lawsuit, which accused J&J's DePuy Orthopaedics unit of defrauding the federal government by marketing defective hip implants, was dismissed in December 2021. J&J has denied wrongdoing.
Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.
Biohaven is coming "out of stealth mode," an analyst said Thursday as BHVN stock climbed for a fourth consecutive day.